# Dermata Therapeutics, Inc.: overview DRMA · Nasdaq · CIK 1853816 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/drma.md) · [Financials](/companies/drma/financials.md) · [Filings](/companies/drma/filings.md) · [Insiders](/companies/drma/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(20.41)](/filings/0001493152-25-023474.md) | not reported | [(4.47)](/filings/0001493152-26-022719.md) | [(1.66)](/filings/0001493152-26-037127.md) | [(1.65)](/filings/0001493152-25-023474.md) | not reported | [(0.48)](/filings/0001493152-26-022719.md) | [(0.74)](/filings/0001493152-26-037127.md) | | Free cash flow | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $ | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | not reported | not reported | [(39.99)](/filings/0001654954-25-002885.md) | [(80.32)](/filings/0001493152-26-012992.md) | [(8.16)](/filings/0001493152-26-012992.md) | | Free cash flow | $ | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/drma/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $26.1k | 20,203 | | Reduced −28,131 | | [Welch & Forbes LLC](/funds/105495.md) | 2026-06-30 | $25.8k | 20,000 | | Unchanged | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $24.2k | 18,747 | | New +18,747 | | [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $21.7k | 16,796 | | Reduced −18,812 | | [SUSQUEHANNA INTERNATIONAL GROUP, LLP](/funds/1446194.md) | 2026-06-30 | $20.6k | 15,989 | | New +15,989 | | [XTX Topco Ltd](/funds/1828301.md) | 2026-06-30 | $19.1k | 14,787 | | New +14,787 | | [Advisory Alpha, LLC](/funds/1576762.md) | 2026-06-30 | $12.9k | 10,000 | | New +10,000 | | [Tower Research Capital LLC (TRC)](/funds/1533421.md) | 2026-06-30 | $5.0k | 3,860 | | Added +3,144 | | [MCF Advisors LLC](/funds/1602905.md) | 2026-06-30 | $2.2k | 1,732 | | Unchanged | | [BARCLAYS PLC](/funds/312069.md) | 2026-06-30 | $348 | 270 | | New +270 | ## Recent filings [All 369 filings](/companies/drma/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-08-17 | 08:30 ET | [8-K](/filings/0001493152-26-038647.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-26-038647 | | 2026-08-11 | 16:07 ET | [10-Q](/filings/0001493152-26-037127.md) | Quarterly report, period 2026-06-30 | 0001493152-26-037127 | | 2026-08-11 | 16:06 ET | [8-K](/filings/0001493152-26-037124.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001493152-26-037124 | | 2026-08-05 | 08:30 ET | [8-K](/filings/0001493152-26-036109.md) | 8.01 Other events | 0001493152-26-036109 | | 2026-06-01 | 16:34 ET | [SCHEDULE 13D](/filings/0001493152-26-026642.md) | Ownership report, active investor | 0001493152-26-026642 | | 2026-05-27 | 16:57 ET | [8-K](/filings/0001493152-26-025441.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001493152-26-025441 | | 2026-05-13 | 16:08 ET | [10-Q](/filings/0001493152-26-022719.md) | Quarterly report, period 2026-03-31 | 0001493152-26-022719 | | 2026-05-13 | 16:05 ET | [8-K](/filings/0001493152-26-022710.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001493152-26-022710 | | 2026-04-17 | 17:01 ET | [DEF 14A](/filings/0001493152-26-017909.md) | Proxy statement, period 2026-04-17 | 0001493152-26-017909 | | 2026-03-26 | 17:17 ET | [10-K](/filings/0001493152-26-012992.md) | Annual report, period 2025-12-31 | 0001493152-26-012992 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001493152-26-012992.md), filed Mar 26, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1853816 - Tickers: DRMA - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 17:27 ET. No prices; not investment advice.